Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
25.60
1.37 (5.65%)
At close: Sep 24, 2025, 3:59 PM
25.79
0.74%
After-hours: Sep 24, 2025, 06:57 PM EDT
Celldex Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant Revenue | 723K | 645K | 3.67M | 3.19M | 2.5M | 154K | 5.39M | 1.51M | 252K | 967K | 1.59M | 153K | 3.45M | 682K | 3.78M | 656K | 236K | 2.29M | 793K | 491K | 195K | 1.3M |
| Grant Revenue Growth | +12.09% | -82.40% | +14.96% | +27.62% | +1522.08% | -97.14% | +255.51% | +501.19% | -73.94% | -39.07% | +937.25% | -95.57% | +406.45% | -81.96% | +476.37% | +177.97% | -89.68% | +188.27% | +61.51% | +151.79% | -84.95% | n/a |
| Service Revenue | 7K | 50K | 8K | 3K | 2K | 2K | 262K | 2K | 16K | n/a | 26K | n/a | 26K | 3K | 4K | 12K | -1K | 442K | 94K | 55K | 520K | 129K |
| Service Revenue Growth | -86.00% | +525.00% | +166.67% | +50.00% | 0.00% | -99.24% | +13000.00% | -87.50% | n/a | n/a | n/a | -100.00% | +766.67% | -25.00% | -66.67% | -1300.00% | -100.23% | +370.21% | +70.91% | -89.42% | +303.10% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 10.39M | 10.82M | 10.26M | 10.05M | 9.13M | 9.1M | 8.83M | 8.22M | 7.22M | 6.64M | 6.6M | 6.53M | 7.15M | 6.91M | 6.24M | 5.82M | 4.31M | 4.12M | 3.62M | 3.64M | 3.53M | 3.67M | 3.22M | 3.4M | 3.91M | 4.9M | 4.33M | 3.72M | 5.62M | 5.59M | 5.89M | 5.35M | 6.53M | 7.23M | 11.93M | 6.95M | 7.79M | 9.31M | 11.07M | 8.49M | 8.18M | 6.09M |
| Selling, General, and Administrative Revenue Growth | -3.96% | +5.43% | +2.08% | +10.14% | +0.27% | +3.07% | +7.43% | +13.85% | +8.75% | +0.64% | +1.03% | -8.71% | +3.52% | +10.74% | +7.22% | +35.18% | +4.49% | +13.75% | -0.47% | +3.17% | -3.76% | +13.89% | -5.41% | -12.92% | -20.18% | +13.02% | +16.39% | -33.78% | +0.50% | -5.11% | +10.25% | -18.18% | -9.61% | -39.42% | +71.70% | -10.78% | -16.30% | -15.96% | +30.49% | +3.70% | +34.41% | n/a |
| Research and Development Revenue | 54.2M | 52.61M | 46.12M | 3K | 38.89M | 30.89M | 29.67M | 34.53M | 26.25M | 26.8M | 22.9M | 21.57M | 20.73M | 17.06M | 14.68M | 13.56M | 12.36M | 12.72M | 10.43M | 10.71M | 9.71M | 11.7M | 10.34M | 11.1M | 10.08M | 11.15M | 11.21M | 11.92M | 21.45M | 21.88M | 23.46M | 21.91M | 25M | 25.79M | 24.56M | 25.01M | 25.71M | 27.45M | 23.9M | 24.66M | 26.49M | 25.13M |
| Research and Development Revenue Growth | +3.01% | +14.08% | +1537233.33% | -99.99% | +25.91% | +4.11% | -14.10% | +31.55% | -2.04% | +17.02% | +6.16% | +4.06% | +21.55% | +16.20% | +8.27% | +9.72% | -2.86% | +22.01% | -2.64% | +10.33% | -17.02% | +13.12% | -6.86% | +10.12% | -9.60% | -0.50% | -5.97% | -44.43% | -1.95% | -6.77% | +7.07% | -12.34% | -3.08% | +5.03% | -1.80% | -2.73% | -6.32% | +14.84% | -3.07% | -6.92% | +5.43% | n/a |